Well Lead Medical Co., Ltd. (SHA:603309)
China · Delayed Price · Currency is CNY 14.20
+0.20 (1.43%)
May 8, 2026, 3:00 PM CST
Well Lead Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,640 | 1,631 | 1,480 | 1,366 | 1,354 | 1,106 |
Other Revenue | - | - | 29.52 | 21.97 | 9.63 | 12.68 |
| 1,640 | 1,631 | 1,509 | 1,388 | 1,363 | 1,119 | |
Revenue Growth (YoY) | 5.92% | 8.07% | 8.76% | 1.79% | 21.88% | -1.07% |
Cost of Revenue | 900.4 | 901.44 | 846.46 | 762.64 | 784.98 | 646.82 |
Gross Profit | 739.6 | 729.74 | 662.88 | 625.1 | 578.37 | 471.76 |
Selling, General & Admin | 303.62 | 301.5 | 288.14 | 292.06 | 286.47 | 255.91 |
Research & Development | 116.64 | 115.66 | 111.11 | 94.92 | 82.07 | 55.03 |
Other Operating Expenses | 9.03 | 7.98 | 8.52 | 2.91 | 14.09 | 10.83 |
Operating Expenses | 428.31 | 425.13 | 407.98 | 390.68 | 381.24 | 322.6 |
Operating Income | 311.29 | 304.6 | 254.9 | 234.42 | 197.13 | 149.16 |
Interest Expense | -1.12 | - | -12.32 | -9.12 | -7.87 | -8.49 |
Interest & Investment Income | 1.2 | 1.68 | 12.32 | 12.2 | 7.53 | 1.38 |
Currency Exchange Gain (Loss) | - | - | 5.07 | 0.91 | 7.4 | -1.64 |
Other Non Operating Income (Expenses) | -25.82 | -21.07 | -0.34 | 0.26 | -1.4 | -1.47 |
EBT Excluding Unusual Items | 285.55 | 285.22 | 259.64 | 238.67 | 202.79 | 138.94 |
Gain (Loss) on Sale of Investments | 1.38 | 1.59 | 0.62 | 0.08 | 1.94 | -4.84 |
Gain (Loss) on Sale of Assets | 0.05 | 0.04 | 0.43 | 0.09 | -0.07 | 0 |
Asset Writedown | -155.28 | -156.57 | -1.34 | -0.46 | -7.47 | -0.56 |
Other Unusual Items | - | - | 3.7 | -1.08 | 8.46 | 6.69 |
Pretax Income | 131.7 | 130.28 | 263.04 | 237.3 | 205.65 | 140.22 |
Income Tax Expense | 43.26 | 43.16 | 34.57 | 32.7 | 27.9 | 25.55 |
Earnings From Continuing Operations | 88.44 | 87.13 | 228.47 | 204.6 | 177.75 | 114.67 |
Minority Interest in Earnings | -11.09 | -10.8 | -9.08 | -12.12 | -11.18 | -8.58 |
Net Income | 77.35 | 76.33 | 219.39 | 192.49 | 166.57 | 106.09 |
Net Income to Common | 77.35 | 76.33 | 219.39 | 192.49 | 166.57 | 106.09 |
Net Income Growth | -66.08% | -65.21% | 13.98% | 15.56% | 57.00% | -30.71% |
Shares Outstanding (Basic) | 291 | 294 | 293 | 292 | 292 | 259 |
Shares Outstanding (Diluted) | 291 | 294 | 293 | 292 | 292 | 259 |
Shares Change (YoY) | -0.34% | 0.36% | 0.30% | -0.20% | 12.93% | -0.29% |
EPS (Basic) | 0.27 | 0.26 | 0.75 | 0.66 | 0.57 | 0.41 |
EPS (Diluted) | 0.27 | 0.26 | 0.75 | 0.66 | 0.57 | 0.41 |
EPS Growth | -65.97% | -65.33% | 13.64% | 15.79% | 39.02% | -30.51% |
Free Cash Flow | 159.44 | 124.11 | -9.47 | -135.38 | 209.75 | 78 |
Free Cash Flow Per Share | 0.55 | 0.42 | -0.03 | -0.46 | 0.72 | 0.30 |
Dividend Per Share | - | - | 0.500 | 0.500 | 0.340 | 0.135 |
Dividend Growth | - | - | - | 47.06% | 151.85% | -32.50% |
Gross Margin | 45.10% | 44.74% | 43.92% | 45.04% | 42.42% | 42.18% |
Operating Margin | 18.98% | 18.67% | 16.89% | 16.89% | 14.46% | 13.33% |
Profit Margin | 4.72% | 4.68% | 14.54% | 13.87% | 12.22% | 9.49% |
Free Cash Flow Margin | 9.72% | 7.61% | -0.63% | -9.75% | 15.38% | 6.97% |
EBITDA | 397.06 | 385.7 | 317.3 | 297.58 | 253.46 | 198.48 |
EBITDA Margin | 24.21% | 23.65% | 21.02% | 21.44% | 18.59% | 17.74% |
D&A For EBITDA | 85.77 | 81.1 | 62.4 | 63.16 | 56.33 | 49.32 |
EBIT | 311.29 | 304.6 | 254.9 | 234.42 | 197.13 | 149.16 |
EBIT Margin | 18.98% | 18.67% | 16.89% | 16.89% | 14.46% | 13.33% |
Effective Tax Rate | 32.85% | 33.13% | 13.14% | 13.78% | 13.57% | 18.22% |
Revenue as Reported | 8.82 | - | 1,509 | 1,388 | 1,363 | 1,119 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.